Schoenberg Mark's Form 4 filing
UroGen Pharma Ltd. (URGN) · filed Feb 4, 2025
- Accession no.
- 0001437749-25-002688
- Filed
- Feb 4, 2025
- Trade date
- Jan 31, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 6 non-derivative transactions and 4 derivative transactions. Open-market sales total $50.7K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Schoenberg MarkCIK 0001763581 | Officer (Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 31, 2025 | Ordinary Shares | MOption exerciseAcquired | +1,334 | – | – | 146,425 | Direct | |
| Jan 31, 2025 | Ordinary Shares | SSaleDisposed | −759 | $11.14 | −$8,455.26 | 145,666 | Direct | |
| Jan 31, 2025 | Ordinary Shares | MOption exerciseAcquired | +3,333 | – | – | 148,999 | Direct | |
| Jan 31, 2025 | Ordinary Shares | SSaleDisposed | −1,896 | $11.14 | −$21,121.44 | 147,103 | Direct | |
| Jan 31, 2025 | Ordinary Shares | MOption exerciseAcquired | +3,333 | – | – | 150,436 | Direct | |
| Jan 31, 2025 | Ordinary Shares | SSaleDisposed | −1,896 | $11.14 | −$21,121.44 | 148,540 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 31, 2025 | Ordinary Shares | MOption exerciseDisposed | −1,334 | $0.00 | $0 | 0 | Direct | |
| Jan 31, 2025 | Ordinary Shares | MOption exerciseDisposed | −3,333 | $0.00 | $0 | 3,334 | Direct | |
| Jan 31, 2025 | Ordinary Shares | MOption exerciseDisposed | −3,333 | $0.00 | $0 | 6,667 | Direct | |
| Jan 31, 2025 | Ordinary Shares | AGrant or awardAcquired | +20,000 | $0.00 | $0 | 20,000 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.